SAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a report published on Tuesday morning, Benzinga reports. Chardan Capital currently has a $25.00 target price on the stock.

Separately, HC Wainwright lowered their price target on SAB Biotherapeutics from $10.00 to $6.00 and set a buy rating on the stock in a research report on Tuesday, April 2nd.

SAB Biotherapeutics Stock Down 3.8 %

Shares of SABS opened at $4.29 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.45 and a quick ratio of 5.45. SAB Biotherapeutics has a 1 year low of $4.00 and a 1 year high of $11.90. The stock has a 50 day simple moving average of $4.89 and a 200-day simple moving average of $3.16.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Citadel Advisors LLC acquired a new stake in SAB Biotherapeutics during the 3rd quarter valued at $28,000. HighTower Advisors LLC bought a new stake in shares of SAB Biotherapeutics during the fourth quarter worth $44,000. Renaissance Technologies LLC acquired a new stake in shares of SAB Biotherapeutics in the second quarter valued at $45,000. Kestra Advisory Services LLC raised its holdings in shares of SAB Biotherapeutics by 319.0% in the fourth quarter. Kestra Advisory Services LLC now owns 88,000 shares of the company’s stock valued at $60,000 after buying an additional 67,000 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in SAB Biotherapeutics during the 2nd quarter worth about $93,000. Institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.